NASDAQ:ATYR aTyr Pharma (ATYR) Stock Price, News & Analysis $4.70 -0.02 (-0.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.73 +0.03 (+0.72%) As of 08/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About aTyr Pharma Stock (NASDAQ:ATYR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get aTyr Pharma alerts:Sign Up Key Stats Today's Range$4.47▼$4.7650-Day Range$3.75▼$6.6152-Week Range$1.67▼$7.29Volume4.25 million shsAverage Volume5.74 million shsMarket Capitalization$418.30 millionP/E RatioN/ADividend YieldN/APrice Target$20.20Consensus RatingBuy Company Overview aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA. Read More aTyr Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreATYR MarketRank™: aTyr Pharma scored higher than 52% of companies evaluated by MarketBeat, and ranked 491st out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingaTyr Pharma has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageaTyr Pharma has only been the subject of 2 research reports in the past 90 days.Read more about aTyr Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for aTyr Pharma are expected to grow in the coming year, from ($0.91) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of aTyr Pharma is -5.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of aTyr Pharma is -5.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioaTyr Pharma has a P/B Ratio of 5.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about aTyr Pharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.68% of the float of aTyr Pharma has been sold short.Short Interest Ratio / Days to CoveraTyr Pharma has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in aTyr Pharma has recently increased by 10.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldaTyr Pharma does not currently pay a dividend.Dividend GrowthaTyr Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted23.68% of the float of aTyr Pharma has been sold short.Short Interest Ratio / Days to CoveraTyr Pharma has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in aTyr Pharma has recently increased by 10.40%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News Sentiment0.86 News SentimentaTyr Pharma has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for aTyr Pharma this week, compared to 3 articles on an average week.Search Interest30 people have searched for ATYR on MarketBeat in the last 30 days. This is an increase of 58% compared to the previous 30 days.MarketBeat Follows20 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 82% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, aTyr Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of aTyr Pharma is held by insiders.Percentage Held by Institutions61.72% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about aTyr Pharma's insider trading history. Receive ATYR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ATYR Stock News HeadlinesInvestors Purchase High Volume of aTyr Pharma Put Options (NASDAQ:ATYR)July 30 at 2:35 AM | americanbankingnews.comaTyr Pharma Shares Hit 52-Week High After Efzofitimod Trial MilestoneJuly 25, 2025 | marketwatch.comOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.August 2 at 2:00 AM | InvestorPlace (Ad)aTyr Pharma announces last patient visit in Phase 3 EFZO-FIT studyJuly 22, 2025 | msn.comaTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary SarcoidosisJuly 22, 2025 | globenewswire.comFavourable Signals For aTyr Pharma: Numerous Insiders Acquired StockJuly 8, 2025 | finance.yahoo.comaTyr Pharma Inc Executives - MorningstarJuly 3, 2025 | morningstar.comMaTyr Pharma (ATYR) Gets a Buy from H.C. WainwrightJuly 2, 2025 | theglobeandmail.comSee More Headlines ATYR Stock Analysis - Frequently Asked Questions How have ATYR shares performed this year? aTyr Pharma's stock was trading at $3.62 at the start of the year. Since then, ATYR stock has increased by 29.8% and is now trading at $4.70. How were aTyr Pharma's earnings last quarter? aTyr Pharma, Inc. (NASDAQ:ATYR) announced its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02. Who are aTyr Pharma's major shareholders? Top institutional shareholders of aTyr Pharma include D.A. Davidson & CO. (0.04%), Apollon Wealth Management LLC (0.02%) and Farther Finance Advisors LLC (0.02%). Insiders that own company stock include Paul Schimmel, Jill Marie Broadfoot, Nancy Denyes and Jane A Gross. View institutional ownership trends. How do I buy shares of aTyr Pharma? Shares of ATYR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that aTyr Pharma investors own include ChargePoint (CHPT), Plug Power (PLUG), Chemomab Therapeutics (CMMB), Curaleaf (CURLF), Dare Bioscience (DARE), Jiuzi (JZXN) and Adial Pharmaceuticals (ADIL). Company Calendar Last Earnings5/07/2025Today8/02/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATYR Previous SymbolNASDAQ:ATYR CIK1339970 WebN/A Phone(858) 731-8389Fax858-731-8394Employees53Year FoundedN/APrice Target and Rating Average Price Target for aTyr Pharma$20.20 High Price Target$35.00 Low Price Target$9.00 Potential Upside/Downside+329.8%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$64.02 million Net MarginsN/A Pretax Margin-27,243.40% Return on Equity-87.09% Return on Assets-64.77% Debt Debt-to-Equity Ratio0.01 Current Ratio7.79 Quick Ratio7.79 Sales & Book Value Annual Sales$230 thousand Price / Sales1,818.70 Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book5.66Miscellaneous Outstanding Shares89,000,000Free Float85,711,000Market Cap$418.30 million OptionableOptionable Beta0.94 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:ATYR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.